188 related articles for article (PubMed ID: 22641291)
1. Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53.
Almazi JG; Mactier S; Best OG; Crossett B; Mulligan SP; Christopherson RI
Proteomics Clin Appl; 2012 Jun; 6(5-6):279-90. PubMed ID: 22641291
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of action of fludarabine nucleoside against human Raji lymphoma cells.
Christopherson RI; Mactier S; Almazi JG; Kohnke PL; Best OG; Mulligan SP
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):375-83. PubMed ID: 24940695
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine nucleoside induces major changes in the p53 interactome in human B-lymphoid cancer cell lines.
Almazi JG; Alomari M; Belov L; Best OG; Shen Y; Graham ME; Mulligan SP; Christopherson RI
Nucleosides Nucleotides Nucleic Acids; 2022; 41(3):314-320. PubMed ID: 34886743
[TBL] [Abstract][Full Text] [Related]
4. The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.
Kaufman KL; Jenkins Y; Alomari M; Mirzaei M; Best OG; Pascovici D; Mactier S; Mulligan SP; Haynes PA; Christopherson RI
Oncotarget; 2015 Dec; 6(38):40981-97. PubMed ID: 26556860
[TBL] [Abstract][Full Text] [Related]
5. Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.
Alonso R; López-Guerra M; Upshaw R; Bantia S; Smal C; Bontemps F; Manz C; Mehrling T; Villamor N; Campo E; Montserrat E; Colomer D
Blood; 2009 Aug; 114(8):1563-75. PubMed ID: 19541822
[TBL] [Abstract][Full Text] [Related]
6. Functional interplay between MDM2, p63/p73 and mutant p53.
Stindt MH; Muller PA; Ludwig RL; Kehrloesser S; Dötsch V; Vousden KH
Oncogene; 2015 Aug; 34(33):4300-10. PubMed ID: 25417702
[TBL] [Abstract][Full Text] [Related]
7. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53.
Davison TS; Vagner C; Kaghad M; Ayed A; Caput D; Arrowsmith CH
J Biol Chem; 1999 Jun; 274(26):18709-14. PubMed ID: 10373484
[TBL] [Abstract][Full Text] [Related]
8. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress.
Murray-Zmijewski F; Lane DP; Bourdon JC
Cell Death Differ; 2006 Jun; 13(6):962-72. PubMed ID: 16601753
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of p53 family proteins in colorectal adenomas and carcinomas: Prognostic and predictive values.
Bahnassy AA; Zekri AR; Salem SE; Abou-Bakr AA; Sakr MA; Abdel-Samiaa AG; Al-Bradei M
Histol Histopathol; 2014 Feb; 29(2):207-16. PubMed ID: 23996743
[TBL] [Abstract][Full Text] [Related]
10. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.
Gaiddon C; Lokshin M; Ahn J; Zhang T; Prives C
Mol Cell Biol; 2001 Mar; 21(5):1874-87. PubMed ID: 11238924
[TBL] [Abstract][Full Text] [Related]
11. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.
Best OG; Che Y; Singh N; Forsyth C; Christopherson RI; Mulligan SP
Leuk Lymphoma; 2012 Jul; 53(7):1367-75. PubMed ID: 22149137
[TBL] [Abstract][Full Text] [Related]
12. p73 and p63 sustain cellular growth by transcriptional activation of cell cycle progression genes.
Lefkimmiatis K; Caratozzolo MF; Merlo P; D'Erchia AM; Navarro B; Levrero M; Sbisa' E; Tullo A
Cancer Res; 2009 Nov; 69(22):8563-71. PubMed ID: 19861536
[TBL] [Abstract][Full Text] [Related]
13. iASPP inhibits p53-independent apoptosis by inhibiting transcriptional activity of p63/p73 on promoters of proapoptotic genes.
Cai Y; Qiu S; Gao X; Gu SZ; Liu ZJ
Apoptosis; 2012 Aug; 17(8):777-83. PubMed ID: 22538442
[TBL] [Abstract][Full Text] [Related]
14. Diverse p63 and p73 isoforms regulate Δ133p53 expression through modulation of the internal TP53 promoter activity.
Marcel V; Petit I; Murray-Zmijewski F; Goullet de Rugy T; Fernandes K; Meuray V; Diot A; Lane DP; Aberdam D; Bourdon JC
Cell Death Differ; 2012 May; 19(5):816-26. PubMed ID: 22075982
[TBL] [Abstract][Full Text] [Related]
15. Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck.
Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A
Int J Cancer; 2002 May; 99(1):22-8. PubMed ID: 11948487
[TBL] [Abstract][Full Text] [Related]
16. The p53 family: same response, different signals?
Chen X
Mol Med Today; 1999 Sep; 5(9):387-92. PubMed ID: 10462750
[TBL] [Abstract][Full Text] [Related]
17. p73 tumor suppressor protein: a close relative of p53 not only in structure but also in anti-cancer approach?
Zawacka-Pankau J; Kostecka A; Sznarkowska A; Hedström E; Kawiak A
Cell Cycle; 2010 Feb; 9(4):720-8. PubMed ID: 20160513
[TBL] [Abstract][Full Text] [Related]
18. From p63 to p53 across p73.
Strano S; Rossi M; Fontemaggi G; Munarriz E; Soddu S; Sacchi A; Blandino G
FEBS Lett; 2001 Feb; 490(3):163-70. PubMed ID: 11223031
[TBL] [Abstract][Full Text] [Related]
19. The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex.
Boominathan L
PLoS One; 2010 May; 5(5):e10615. PubMed ID: 20485546
[TBL] [Abstract][Full Text] [Related]
20. Differential regulation of vitamin D receptor (VDR) by the p53 Family: p73-dependent induction of VDR upon DNA damage.
Kommagani R; Payal V; Kadakia MP
J Biol Chem; 2007 Oct; 282(41):29847-54. PubMed ID: 17716971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
